Truist Financial Corp Harmony Biosciences Holdings, Inc. Transaction History

Truist Financial Corp

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 20, 2024	BUY	$28.81 - $33.01 $374 - $429	13 Added 0.14%	8,979 $270,000
Q1 2024 May 10, 2024	SELL	$29.93 - $35.06 $6,614 - $7,748	-221 Reduced 2.41%	8,966 $301,000
Q4 2023 Feb 02, 2024	BUY	$19.2 - $33.78 $176,390 - $310,336	9,187 New	9,187 $296,000
Q2 2023 Aug 01, 2023	SELL	$30.5 - $37.4 $41,632 - $51,051	-1,365 Reduced 18.17%	6,149 $216,000
Q1 2023 May 05, 2023	BUY	$30.8 - $53.92 $492 - $862	16 Added 0.21%	7,514 $245,000
Q4 2022 Feb 17, 2023	BUY	$45.4 - $60.91 $340,409 - $456,703	7,498 New	7,498 $413,000

242

45.1M

108K

49.2K

Ticker HRMY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,161,400
Market Cap $2.02B
Description
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony ...

Get notified when there are updates to the investment portfolio of Truist Financial Corp, based on Form 13F filings with the SEC.

Stay updated on Truist Financial Corp with notifications on news.